Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.52 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.51 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.51 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.50 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.47 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24742723 | 1.00 | CRBN (0.54) | CRBNDDB1IKZF2IKZF1CSNK1A1 | |
| SCHEMBL25010545 | 0.89 | CRBN (0.60) | CRBNDDB1IKZF2IKZF1 | |
| SCHEMBL24745530 | 0.88 | CRBN (0.51) | CRBNDDB1IKZF2IKZF1CSNK1A1 | |
| SCHEMBL30122031 | 0.88 | CRBN (0.51) | CRBNDDB1IKZF2IKZF1CSNK1A1 | |
| SCHEMBL24817924 | 0.86 | CRBN (0.54) | CRBNIKZF2IKZF1IKZF3 | |
| SCHEMBL20046850 | 0.85 | CRBN (0.52) | CRBNIKZF2IKZF1CSNK1A1IKZF3 | |
| SCHEMBL25010101 | 0.85 | CRBN (0.67) | CRBNDDB1IKZF2IKZF1IKZF3 | |
| SCHEMBL24816878 | 0.84 | CRBN (0.53) | CRBNIKZF2IKZF1CSNK1A1IKZF3 | |
| SCHEMBL24745083 | 0.84 | CRBN (0.63) | CRBNIKZF2IKZF1CSNK1A1 | |
| SCHEMBL30270874 | 0.84 | CRBN (0.63) | CRBNIKZF2IKZF1CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294499-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2024-09-05 | — | — | US | disclosed |
| EP-4347579-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | Captor Therapeutics S.A. (PL) | 2024-04-10 | — | — | EP | disclosed |
| WO-2022253713-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294499-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | MCL1, MDM2, XIAP | CRBN 149/4885DDB1 133/4885IKZF2 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.